BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 20577273)

  • 1. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration.
    Vallance JH; Johnson B; Majid MA; Banerjee S; Mandal K; Bailey CC
    Eye (Lond); 2010 Oct; 24(10):1561-7. PubMed ID: 20577273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
    Larsen M; Schmidt-Erfurth U; Lanzetta P; Wolf S; Simader C; Tokaji E; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):992-1000. PubMed ID: 22424834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
    Kaiser PK; Boyer DS; Cruess AF; Slakter JS; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration.
    Sivaprasad S; Patra S; DaCosta J; Adewoyin T; Shona O; Pearce E; Chong NV
    Ophthalmologica; 2011; 225(4):200-6. PubMed ID: 21293163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H; Abrams P
    Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
    Antoszyk AN; Tuomi L; Chung CY; Singh A;
    Am J Ophthalmol; 2008 May; 145(5):862-74. PubMed ID: 18321465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravitreal ranibizumab in combination with verteporfin photodynamic therapy in neovascular macular degeneration].
    Soucek P; Soucková I
    Cesk Slov Oftalmol; 2008 Jul; 64(4):135-40. PubMed ID: 18780651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
    Brown DM; Kaiser PK; Michels M; Soubrane G; Heier JS; Kim RY; Sy JP; Schneider S;
    N Engl J Med; 2006 Oct; 355(14):1432-44. PubMed ID: 17021319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
    Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY;
    Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation.
    Seidel G; Werner C; Weger M; Steinbrugger I; Haas A
    Acta Ophthalmol; 2013 Sep; 91(6):e482-5. PubMed ID: 23786546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
    Koh A; Lee WK; Chen LJ; Chen SJ; Hashad Y; Kim H; Lai TY; Pilz S; Ruamviboonsuk P; Tokaji E; Weisberger A; Lim TH
    Retina; 2012 Sep; 32(8):1453-64. PubMed ID: 22426346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.
    Bressler NM; Chang TS; Fine JT; Dolan CM; Ward J;
    Arch Ophthalmol; 2009 Jan; 127(1):13-21. PubMed ID: 19139332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination photodynamic therapy and intravitreal ranibizumab in neovascular age-related macular degeneration in a North Indian population: a pilot study.
    Kumar A; Gopalakrishnan K; Sinha S
    Retina; 2008 Oct; 28(9):1296-301. PubMed ID: 18667951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration.
    Krebs I; Vécsei Marlovits V; Bodenstorfer J; Glittenberg C; Ansari Shahrezaei S; Ristl R; Binder S
    Acta Ophthalmol; 2013 May; 91(3):e178-83. PubMed ID: 23241227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration.
    Forte R; Bonavolontà P; Benayoun Y; Adenis JP; Robert PY
    Ophthalmic Res; 2011; 45(3):129-34. PubMed ID: 20847575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey.
    Husain D; Kim I; Gauthier D; Lane AM; Tsilimbaris MK; Ezra E; Connolly EJ; Michaud N; Gragoudas ES; O'Neill CA; Beyer JC; Miller JW
    Arch Ophthalmol; 2005 Apr; 123(4):509-16. PubMed ID: 15824225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R; Gabric N
    Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
    Bakri SJ; Couch SM; McCannel CA; Edwards AO
    Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.